{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Harvala H"],"funding":["Health Services and Delivery Research Programme","NHS Blood and Transplant","National Institute for Health Research (NIHR)","European Commission"],"pagination":["1347-1354"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9348319"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["62(7)"],"pubmed_abstract":["Background
The therapeutic benefit of convalescent plasma (CP) therapy to treat COVID-19 may derive from neutralizing antibodies (nAbs) to SARS-CoV-2. To investigate the effects of antigenic variation on neutralization potency of CP, we compared nAb titers against prototype and recently emerging strains of SARS-CoV-2, including Delta and Omicron, in CP donors previously infected with SARS-CoV-2 before and after immunization.Methods and materials
Samples were assayed from previously SARS-CoV-2 infected donors before (n = 17) and after one (n = 43) or two (n = 71) doses of Astra-Zeneca or Pfizer vaccinations. Ab titers against Wuhan/wild type (WT), Alpha, Beta, and Delta SARS-CoV-2 strains were determined by live virus microneutralization assay while titers to Omicron used a "],"journal":["Transfusion"],"pubmed_title":["Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization."],"pmcid":["PMC9348319"],"funding_grant_id":["101015756","RECPLAS"],"pubmed_authors":["Mora A","Webster M","Carroll M","Otter A","Clarkson A","Hopkins V","Roberts DJ","Griffiths A","Nguyen D","Lamikanra AA","Laidlaw SM","Maes P","Kaloyirou F","Simmonds P","Estcourt L","MacLennan S","Harvala H","Tsang HP"],"additional_accession":[]},"is_claimable":false,"name":"Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization.","description":"Background
The therapeutic benefit of convalescent plasma (CP) therapy to treat COVID-19 may derive from neutralizing antibodies (nAbs) to SARS-CoV-2. To investigate the effects of antigenic variation on neutralization potency of CP, we compared nAb titers against prototype and recently emerging strains of SARS-CoV-2, including Delta and Omicron, in CP donors previously infected with SARS-CoV-2 before and after immunization.Methods and materials
Samples were assayed from previously SARS-CoV-2 infected donors before (n = 17) and after one (n = 43) or two (n = 71) doses of Astra-Zeneca or Pfizer vaccinations. Ab titers against Wuhan/wild type (WT), Alpha, Beta, and Delta SARS-CoV-2 strains were determined by live virus microneutralization assay while titers to Omicron used a ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jul","modification":"2025-04-18T18:07:16.924Z","creation":"2025-04-07T05:45:32.196Z"},"accession":"S-EPMC9348319","cross_references":{"pubmed":["35588314"],"doi":["10.1111/trf.16934"]}}